HLB "Riboceranib Shows Excellent Efficacy in Bone and Soft Tissue Sarcoma"

[Asia Economy Reporter Hyunseok Yoo] HL Biopharma announced on the 19th that its anticancer drug 'Rivoceranib (Chinese name Apatinib)' has demonstrated excellent efficacy not only as a monotherapy for gastric cancer and thymic carcinoma but also for bone sarcoma and soft tissue sarcoma.

The Air Force Medical University of China conducted a meta-analysis (a research method that collects and reanalyzes multiple study results on a specific research topic) of data from 827 patients with bone and soft tissue sarcomas and 21 related studies published in recent years, and published the results on the 17th in the Swiss medical journal Frontiers in Oncology.

The study targeting angiogenesis inhibitors (VEGFR-2 inhibitors) included comparisons of Rivoceranib with Sorafenib, Pazopanib, and Anlotinib. The clinical subjects consisted of 827 patients treated with Rivoceranib, 101 with Sorafenib, 246 with Pazopanib, and 166 with Anlotinib, with Rivoceranib studies overwhelmingly representing the majority of the data.

Clinical results showed an ORR (Objective Response Rate) of 23.85% for Rivoceranib, 14.47% for Sorafenib, 5.56% for Pazopanib, and 12.65% for Anlotinib. The DCR (Disease Control Rate) was 79.16% for Rivoceranib, 47.36% for Sorafenib, 72.36% for Pazopanib, and 74% for Anlotinib, indicating that Rivoceranib exhibited a higher response rate compared to other treatments. In terms of PFS (Progression-Free Survival), Rivoceranib showed 7.08 months, Sorafenib 4.2 months, Pazopanib 4.6 months, and Anlotinib 5.6 months, demonstrating superior survival rates compared to drugs with the same mechanism of action. This proves that Rivoceranib could be a promising treatment option for sarcomas following its success in solid tumors. The broad versatility of Rivoceranib, which inhibits tumor growth and metastasis through angiogenesis suppression, has been confirmed once again.

An HL Biopharma representative stated, “In addition to ongoing clinical trials for solid tumors such as gastric cancer, liver cancer, colorectal cancer, and thymic carcinoma, we will actively consider expanding clinical trials to various cancer types including sarcomas. Due to the excellence of Rivoceranib, numerous clinical trials for various indications are being conducted worldwide, and positive results are continuously emerging, greatly aiding the company’s direction and strategic planning.”

This content was produced with the assistance of AI translation services.